COVID‐19 drug repurposing: Summary statistics on current clinical trials and promising untested candidates
Open Access
- 3 July 2020
- journal article
- review article
- Published by Hindawi Limited in Transboundary and Emerging Diseases
- Vol. 68 (2), 313-317
- https://doi.org/10.1111/tbed.13710
Abstract
Repurposing of existing anti‐viral drugs, immunological modulators and supportive therapies represents a promising path towards rapidly developing new control strategies to mitigate the devastating public health consequences of the COVID‐19 pandemic. A comprehensive text‐mining and manual curation approach was used to comb and summarize the most pertinent information from existing clinical trials and previous efforts to develop therapies against related betacoronaviruses, particularly SARS and MERS. In contrast to drugs in current trials, which have been derived overwhelmingly from studies on taxonomically unrelated RNA viruses, a number of untested small molecule anti‐virals had previously demonstrated remarkable in vitro specificity for SARS‐CoV or MERS‐CoV, with high selectivity indices, EC50 and/or IC50. Due to the rapid containment of the prior epidemics, however, these were generally not followed up with in vivo animal studies or clinical investigations and thus largely overlooked as treatment prospects in the current COVID‐19 trials. This brief review summarizes and tabulates core information on recent or ongoing drug repurposing‐focused clinical trials, while detailing the most promising untested candidates with prior documented success against the aetiologic agents of SARS and/or MERS.This publication has 17 references indexed in Scilit:
- Therapeutic options for the 2019 novel coronavirus (2019-nCoV)Nature Reviews Drug Discovery, 2020
- A Data-Driven Approach to Predicting Successes and Failures of Clinical TrialsCell Chemical Biology, 2016
- Anti-SARS coronavirus agents: a patent review (2008 – present)Expert Opinion on Therapeutic Patents, 2013
- Potential antivirals and antiviral strategies against SARS coronavirus infectionsExpert Review of Anti-infective Therapy, 2006
- Expanding the frontiers of existing antiviral drugs: Possible effects of HIV-1 protease inhibitors against SARS and avian influenzaJournal of Clinical Virology, 2005
- Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compoundsAntiviral Research, 2005
- Synthesis and activity of an octapeptide inhibitor designed for SARS coronavirus main proteinasePeptides, 2005
- Cinanserin Is an Inhibitor of the 3C-Like Proteinase of Severe Acute Respiratory Syndrome Coronavirus and Strongly Reduces Virus Replication In VitroJournal of Virology, 2005
- Inhibition of Severe Acute Respiratory Syndrome-Associated Coronavirus (SARSCoV) by Calpain Inhibitors and β-D-N4-HydroxycytidineAntiviral Chemistry and Chemotherapy, 2004
- Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARSBiochemical and Biophysical Research Communications, 2003